What’s on your mind? Text us now!

Dr. Megan Kruse, a breast medical oncologist at the Cleveland Clinic, shares the significance of HR+ in cancer growth and the delicate balance between anti-estrogen treatment and aggressive approaches. The conversation explores the different options available for HR+ breast cancer patients that include Tamoxifen and aromatase inhibitors, the duration of hormonal therapy and its impact on survival.

Dr. Kruse stresses the importance of understanding patients' hormonal experiences and aligning treatment plans with their overall health goals. They discuss managing symptoms of anti-estrogen treatment like hot flashes, considering both medical and natural remedies. The dialogue also addresses the side effects of aromatase inhibitors compared to Tamoxifen.

Thank you for listening! We are starting small and hoping to grow! Please rate & review each episode. We’d also love to hear your ideas or feedback Info@BreastCancerUnleashed.com

Follow Us!
Facebook:https://www.facebook.com/profile.php?id=100081181223576
Instagram: @breastcancerunleashed
LinkedIn
Twitter: @liabcunleashed
YouTube: @breastcancerunleashed


DISCLAIMER: These podcasts are not intended as medical advice. Please speak with your medical provider about any decisions regrading your health and/or treatment.